321 related articles for article (PubMed ID: 34321321)
1. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.
Sun Y; Chen W; Torphy RJ; Yao S; Zhu G; Lin R; Lugano R; Miller EN; Fujiwara Y; Bian L; Zheng L; Anand S; Gao F; Zhang W; Ferrara SE; Goodspeed AE; Dimberg A; Wang XJ; Edil BH; Barnett CC; Schulick RD; Chen L; Zhu Y
Sci Transl Med; 2021 Jul; 13(604):. PubMed ID: 34321321
[TBL] [Abstract][Full Text] [Related]
2. Structural insight into CD93 recognition by IGFBP7.
Xu Y; Sun Y; Zhu Y; Song G
Structure; 2024 Mar; 32(3):282-291.e4. PubMed ID: 38218180
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization.
Li Y; Fu L; Wu B; Guo X; Shi Y; Lv C; Yu Y; Zhang Y; Liang Z; Zhong C; Han S; Xu F; Tian Y
Cancer Cell Int; 2023 Sep; 23(1):189. PubMed ID: 37660019
[TBL] [Abstract][Full Text] [Related]
4. Structural insight into CD93 recognition by IGFBP7.
Xu Y; Sun Y; Zhu Y; Song G
bioRxiv; 2023 Jun; ():. PubMed ID: 37333140
[TBL] [Abstract][Full Text] [Related]
5. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
Front Immunol; 2022; 13():898493. PubMed ID: 35812369
[TBL] [Abstract][Full Text] [Related]
6. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound Imaging of Tumor Vascular CD93 with MMRN2 Modified Microbubbles for Immune Microenvironment Prediction.
Wang D; Xing C; Liang Y; Wang C; Zhao P; Liang X; Li Q; Yuan L
Adv Mater; 2024 May; 36(18):e2310421. PubMed ID: 38270289
[TBL] [Abstract][Full Text] [Related]
8. Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets.
Guo A; Zhang J; Tian Y; Peng Y; Luo P; Zhang J; Liu Z; Wu W; Zhang H; Cheng Q
Front Immunol; 2022; 13():907182. PubMed ID: 36389798
[TBL] [Abstract][Full Text] [Related]
9. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
[TBL] [Abstract][Full Text] [Related]
10. CD93 Correlates With Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Zhang Z; Zheng M; Ding Q; Liu M
Front Cell Dev Biol; 2022; 10():817965. PubMed ID: 35242761
[No Abstract] [Full Text] [Related]
11. Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
Langenkamp E; Zhang L; Lugano R; Huang H; Elhassan TE; Georganaki M; Bazzar W; Lööf J; Trendelenburg G; Essand M; Pontén F; Smits A; Dimberg A
Cancer Res; 2015 Nov; 75(21):4504-16. PubMed ID: 26363010
[TBL] [Abstract][Full Text] [Related]
12. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
13. CD93 Blockade Stabilizes Tumor Vasculature to Improve Therapy Response.
Cancer Discov; 2021 Oct; 11(10):2368. PubMed ID: 34362767
[TBL] [Abstract][Full Text] [Related]
14. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
15. Blockade of CD93 in pleural mesothelial cells fuels anti-lung tumor immune responses.
Zhang C; Nan X; Zhang B; Wu H; Zeng X; Song Z; Li S; Wang J; Xie S; Zhang G; Xiu H; Wang J; Guo J; Wang P; Cai Z; Zhen Y; Shen Y
Theranostics; 2024; 14(3):1010-1028. PubMed ID: 38250037
[No Abstract] [Full Text] [Related]
16. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
[No Abstract] [Full Text] [Related]
17. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
Lugano R; Vemuri K; Yu D; Bergqvist M; Smits A; Essand M; Johansson S; Dejana E; Dimberg A
J Clin Invest; 2018 Aug; 128(8):3280-3297. PubMed ID: 29763414
[TBL] [Abstract][Full Text] [Related]
18. Dimerization of the C-type lectin-like receptor CD93 promotes its binding to Multimerin-2 in endothelial cells.
Barbera S; Raucci L; Tassone G; Tinti L; Prischi F; Santucci A; Mongiat M; Tosi GM; Galvagni F; Dimberg A; Pozzi C; Orlandini M
Int J Biol Macromol; 2023 Jan; 224():453-464. PubMed ID: 36265539
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium.
Galvagni F; Nardi F; Spiga O; Trezza A; Tarticchio G; Pellicani R; Andreuzzi E; Caldi E; Toti P; Tosi GM; Santucci A; Iozzo RV; Mongiat M; Orlandini M
Matrix Biol; 2017 Dec; 64():112-127. PubMed ID: 28912033
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
